[Skip to Navigation]
Views 867
Citations 0
Comment & Response
August 6, 2020

Assessing Expression of PD-L1 in Tumor-Associated Macrophages

Author Affiliations
  • 1Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China
JAMA Oncol. 2020;6(10):1634. doi:10.1001/jamaoncol.2020.2698

To the Editor We read with interest the article by Jabbour et al1 regarding their phase 1 trial of pembrolizumab administered concurrently with chemoradiotherapy for locally advanced non–small cell lung cancer (NSCLC). This nonrandomized controlled trial highlights that combined treatment for stage III NSCLC is safe and tolerable, with promising progression-free survival; however, we have some questions.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words